Nesia Moradian’s Post

Great insights from revenue cycle leaders at the Mayo Clinic, Kaiser, and Amazon at the #HFMA2024 conference this year! Nikki Harper, Nick Rogers, and Bradley Tinnermon shared their expertise and knowledge. Key lessons: 1) You still need planning and governance... 2) Quality is key - and a prior agreement as what quality means 4) Transparency and reliability are non-negotiable 5) Customization and integration are essential 6) Know what your objectives are, and how to measure success, going in Full article: https://lnkd.in/gjRJVaru

In case you missed our Goodwin + KPMG 5th Annual Symposium during #jpm2024... Make sure to check out this insightful clip from our exclusive guest speaker, Rahul Rao, Deputy Director of FTC's Bureau of Competition, as he discusses the new approaches the #FTC is taking with filings.

Here’s a 2024 #Healthcare Prediction from Greg Samios, President and CEO of Clinical Effectiveness at Wolters Kluwer Health: We predict as healthcare explores #GenAI and patient care, the source and vetting of the underlying content will become a key factor in the speed in which it is deployed. https://lnkd.in/eJh2RK6r

Follow the HPC Advisory Council live now! Council members discuss ongoing access and affordability challenges across the health care system and policy solutions aimed at addressing these, including a proposed affordability index. #healthpolicy #healthcarecosts

A year from now you may wish you had started today Investing in Johnson & Johnson (JNJ): Securing your Health and Wealth 💼📈💰 Tap into the future of healthcare with Johnson & Johnson (JNJ), a renowned American multinational corporation that has been revolutionizing the medical industry since 1886. As an investor, now is the perfect time to seize the opportunity and grow your Health Savings Account (HSA) by investing in this leading company. 🏥💊 Advancing Medical Devices and Pharmaceuticals Johnson & Johnson is at the forefront of cutting-edge medical devices and pharmaceuticals. From groundbreaking surgical tools to life-saving medications, their innovative products cater to diverse healthcare needs. By investing in JNJ, you become part of a company that is actively shaping the future of medicine and improving the well-being of patients worldwide. 📈💪 Boosting Your Investment Portfolio With its strong presence in the Dow Jones Industrial Average and ranking as the 36th largest U.S. corporation on the Fortune 500 list, Johnson & Johnson offers stability and growth potential. By including JNJ in your investment portfolio, you can benefit from consistent performance, capital appreciation, and dividend payouts. ✨💼 Aligning Health and Wealth for a Bright Future Investing in JNJ allows you to align your personal health goals with financial success. By focusing on healthcare-related investments, you not only secure your long-term financial well-being but also contribute to the advancement of the industry, ultimately benefiting society as a whole. ⏳⚠ Act Now to Avoid the Fear of Missing Out! Don't let the Fear of Missing Out (FOMO) hold you back. Take action today and invest in Johnson & Johnson to supercharge your HSA growth potential. Join the ranks of successful investors who are capitalizing on the incredible opportunities offered by healthcare investments. #hsa #investing #healthcare #health #family #wellness 🌟💼💵🌎👨👩👧👦💪 🔮🚀 Invest in Johnson & Johnson for a prosperous future! Act now to secure your health and wealth. 🔥💼📈💰

New Insights on 2024/25 M&A! CBV Institute is pleased to release our latest edition of CBV Insights, highlighting results from the Institute’s 2024 M&A Outlook Survey. Some key findings: 💼 Fifty-eight per cent of CBV respondents expect M&A activity to increase. 💼 The sectors expected to drive this growth are industrial products and services, health care, and technology. 💼 Fifty per cent of CBV respondents expect cross-border M&A activity involving Canadian companies will increase. This survey was developed in close collaboration with Dr. Howard E. Johnson, DBA, FCPA, FCA, FCMA, CPA, CFA, ASA, CF, C.Dir., FCBV, Canadian Market Leader and Managing Director in Kroll’s M&A Advisory Practice. Read more below: #CBVInsights #ThoughtLeadership #BusinessValuation

Here’s a 2024 #Healthcare Prediction from Greg Samios, President and CEO of Clinical Effectiveness at Wolters Kluwer Health: We predict as healthcare explores #GenAI and patient care, the source and vetting of the underlying content will become a key factor in the speed in which it is deployed. https://lnkd.in/eAcHSZNR

The 42nd Annual J.P. Morgan Healthcare Conference recently wrapped up in San Francisco, and the buzz around this event has been undeniable. Even as an observer from afar, the insights and developments shared have been both enlightening and inspiring. Despite the challenges faced by the life sciences industry, attendees reported an optimistic atmosphere. Christopher P. Molineaux, head of Life Sciences Pennsylvania, mentioned an 'optimistic vibe' for our resilient sector. This is indicative of an industry that's not just surviving but thriving #JPM2024. Interestingly, the conference took a more subdued tone this year with fewer big deals being announced. However, this didn't dampen the enthusiasm or depth of discussions. It shows that the value of such events isn't solely about deal-making, but in the exchange of ideas and formation of new partnerships #JPMHC42. One key takeaway was a noticeable shift in investment strategies with VC and PE capital being deployed more thoughtfully and patiently. This underlines the fact that in a rapidly evolving industry like ours, strategy and foresight are just as important as capital #LifeSciences. As Ali Ardakani, a veteran attendee, put it - the value of the conference lies not just in the official events, but in the opportunity for worthwhile meetings and discussions that happen around it #HealthcareConference. As we reflect on the insights from this year's J.P. Morgan Healthcare Conference, we look forward to the innovations and advancements that 2024 will bring in the world of life sciences! #JPM2024 #Healthcare #LifeSciences #Innovation

Remain independent or join a system? That’s the critical decision facing many hospitals today. In this article for AHLA, #ECGMC’s Ed Moran and Jeff Hoffman discuss the factors leaders should consider when assessing the potential for success under each scenario. #mergersandacquisitions #strategicplanning https://lnkd.in/gRpkCa77

Remain independent or join a system? That’s the critical decision facing many hospitals today. In this article for AHLA, #ECGMC’s Ed Moran and Jeff Hoffman discuss the factors leaders should consider when assessing the potential for success under each scenario. #mergersandacquisitions #strategicplanning https://lnkd.in/ecbvcRSR